U.S. stock futures moved higher on Monday as investors welcomed signs of a pause in hostilities between the United States and Iran, helping to ease pressure on energy markets ahead of a crucial week for corporate earnings and central bank decisions.
By 05:49 GMT, Dow Jones futures had gained 398 points, or 0.8%, while S&P 500 futures were up 66 points, or 0.9%. Nasdaq 100 futures led the advance, climbing 406 points, or 1.4%.
Wall Street ended last week on a mixed note as rising oil prices and geopolitical uncertainty weighed on investor sentiment. However, indications that the White House is seeking to avoid a broader military escalation have improved market confidence, pushing oil prices lower while supporting both equities and bond markets.
Investors are now turning their attention to one of the busiest weeks of the earnings season, with around one-third of S&P 500 companies scheduled to publish quarterly results. Overall earnings are forecast to increase by approximately 26.5% compared with the same period last year.
Several of the world's largest technology companies are due to report this week, including Amazon (NASDAQ:AMZN), Meta Platforms (NASDAQ:META), Microsoft (NASDAQ:MSFT) and Apple (NASDAQ:AAPL). Their results are expected to provide fresh insight into whether the rapid pace of investment in artificial intelligence infrastructure can continue, as markets increasingly debate the long-term profitability of AI-related spending.

#points #investors #prices

Starbucks' net income cratered from $4.25 billion to a $2 billion run rate, dragging shares down 17% over five years against the S&P's 70% gain.
CEO Brian Niccol's menu and service changes at SBUX face stiff competition from MCD and Dunkin', making double-digit same-store sales growth essential for a true recovery.
Investors fixated on Starbucks' historically strong earnings may be overlooking whether Niccol's turnaround can ever restore the company's peak profitability.
Act now: the ***** yst who called NVIDIA in 2010 just named his top 10 AI stocks — and McDonald's didn't make the cut. Grab the names FREE today.
What can Starbucks' (NASDAQ: SBUX) management say about its stock? Shares are up 24% this year compared to the S&P, which has risen 9%. Over the last year, it is up 12% compared to the S&P at 19%. Over the last five years, its shares have fallen 17% compared to 70% for the S&P.

#starbucks #billion

Jack Mallers has stepped down as CEO of Twenty One Capital, and investors didn't take it well.
Shares of the Bitcoin treasury company—a publicly traded firm that holds Bitcoin on its balance sheet, letting regular investors gain exposure to the cryptocurrency without buying it directly—dropped nearly 15% on Tuesday.
Mallers co-founded Twenty One alongside Tether—the issuer of USDT, the world's most widely used dollar-pegged stablecoin (a digital token that holds a fixed value of one dollar and functions as the backbone of crypto trading)—and listed the company on the New York Stock Exchange in December 2025 through a ******* merger. A ******* , or special purpose acquisition company, is a blank check shell firm created specifically to take other companies public faster than a traditional IPO allows.
Twenty One still holds 43,514 BTC. At current prices, that balance sheet is worth more than $4 billion, ranking it second among all public companies for Bitcoin holdings, just behind Michael Saylor's Strategy. Strategy is the company that effectively pioneered the corporate Bitcoin treasury playbook in 2020—borrowing money to buy Bitcoin at scale and daring anyone to tell them it was a bad idea.
Mallers' exit comes packaged with worse news. Tether's plan to merge three Bitcoin businesses into a single publicly traded entity has officially collapsed, per Bloomberg. The proposed combination would have united Twenty One's treasury operations, Strike's Bitcoin payments and lending platform (which operates in more than 100 countries), and Elektron Energy's mining infrastructure under one publicly listed company.

#treasury #holds

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. Valued at $166.7 billion by market cap, the company's primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions. The HIV giant is expected to announce its fiscal second-quarter earnings for 2026 in the near term.
Ahead of the event, ******* ysts expect GILD to report a loss of $7.09 per share on a diluted basis, down 452.7% from a profit of $2.01 per share in the year-ago quarter. The company has consistently surpassed the consensus estimates in each of the last four quarters.
Huge, Unusual Intel Options Volume Today Ahead of Earnings This Week
Intel Stock Is Down, But Put Premiums are High - Put Short Sellers Love the High Yields
The Number Tesla Stock Bulls Are Really Waiting for This Earnings Season Has Nothing to Do With Cars

#earnings

Lexeo Therapeutics Inc. (NASDAQ:LXEO) is one of the 10 best stocks under $10 that could triple.
On June 15, Lexeo Therapeutics Inc. (NASDAQ:LXEO) disclosed that it has finalized the critical trial protocol of SUNRISE-FA 2. The company also finalized the statistical ***** ysis plan meant to offer clinical evidence for submission of a Biologics License Application to the U.S. FDA.
Pressmaster/Shutterstock.com
The company highlighted that this submission is for the gene-based therapy candidate, LX2006, under the 2028 approval pathway. Lexeo's Chief Medical Officer, Narinder Bhalla, M.D., labeled it as a major stride that involves the completion of a critical study design for SUNRISE-FA 2. He believes that it sets a path to ***** s LX2006 in Friedreich's ataxia cardiomyopathy. He further stated:
"Patients living with FA, particularly those with cardiac involvement, have a significant unmet need for new treatment options and remain at the center of our efforts. This progress brings us one step closer to delivering a potential new therapy, and we remain focused on execution as we work to initiate the pivotal study and enroll the first patient by the end of the month."

Bitcoin (BTC) was down on Monday as traders awaited the core inflation data, due to release Tuesday, while ***** sing the worsening US–Iran ceasefire conditions.
The BTC/USD exchange rate dropped more than 2% to around $62,500 ahead of the European session, extending its retreat alongside technology stocks.
US-listed shares of South Korean chipmaker SK Hynix plunged roughly 8%, weighing on semiconductor stocks and pushing US equity futures lower.
SK Hynix is the world's second-largest memory-chip maker and Nvidia's (NVDA) main supplier of high-bandwidth memory, a critical component in AI accelerators.
The company controlled about 61% of the global HBM market in 2025, making its stock a key gauge of investor confidence in the AI hardware boom.

NurPhoto/Getty Images
VC funding for European biotech startups is on track for a record year, though the gap with the US remains stark.
According to PitchBook data, €800 million (about $912 million) has been invested in the ****** e this year, more than three-quarters of the total for 2025. At the current pace, deal value would surpass 2018's record of €1.2 billion.
The number of VC rounds involving European biotech startups is expected to increase modestly from last year, unlike in many other sectors. However, the median deal size remains below 2024's high of €3.5 million.
Swiss radiopharmaceutical startup Nuclidium's 105 million Swiss francs (about $130 million) Series B was the largest round to close this year. It is followed by a $115 million Series A for London-based RQ Bio, which develops therapeutics to prevent influenza in immunocompromised people.

Artificial Intelligence has grown in popularity over the past five years, from something consumers only knew from sci-fi movies to a widely used technology. Many companies are now using AI in some form, and it has become part of everyday life for many consumers, with AI services integrated into internet search engines, phone applications, and other daily interactions. However, as AI is deployed at a faster pace, it is becoming clear that the technology cannot be used as extensively as tech companies had hoped, while companies are realising the value of human workers.
Investors have rushed to buy tech stocks on New York stock market indexes, such as the S&P 500 and the tech-heavy Nasdaq, in recent years, as more companies launch AI services. Just seven companies, Amazon, Alphabet (Google), Nvidia, Meta (Facebook), Microsoft, Apple, and Tesla, have dominated this focus. An increasing number of City ******* ysts and financial economists are now warning that the AI bubble will eventually burst.
Jeremy Grantham, the founder and investment adviser at a large ******* et manager, said he planned to sell his tech shares as he expected the AI bubble to burst soon. Grantham said that AI was similar to the invention of railways or the internet in that everyone overinvests and, when they realise it is a utility, such as electricity, they understand that there is not much money to be made from the invention itself, except for the companies that build services around it.
Companies and consumers have been wowed by the capabilities of AI technologies, which appear increasingly intelligent. More and more companies are investing in integrating AI services into their operations, while consumers are using AI for basic, everyday tasks, such as internet searches. However, as AI booms, users are slowly losing confidence in certain services, as it becomes clear that there are limits to AI's "intelligence" or human-like capabilities.
In the manufacturing sector, companies have been investing in automation for decades, as engineering and tech firms develop automated equipment capable of performing simple tasks in place of humans. This has helped speed up production lines, reduce the need for humans to conduct more dangerous or monotonous tasks, and lower the price of goods. However, the advent of AI poses a far greater threat to workers in the sector.